We'd need to know when the DSMB meets, i.e. when a
Post# of 148278
With Mesoblast it was within days:
An independent Data Safety Monitoring Board (DSMB) has set a review date of early September for its first interim analysis of the Phase 3 trial of remestemcel-L in ventilator-dependent COVID-19 patients
with moderate to severe ARDS.
PR with recommendation to continue on September 4 .
http://investorsmedia.mesoblast.com/static-fi...66cd51b4d8